department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

EPIRUBICIN HYDROCHLORIDE · pharmadog

pharmadog
drugs
EPIRUBICIN HYDROCHLORIDE

drug

patient view →

EPIRUBICIN HYDROCHLORIDE

Marketedupdated 2mo ago

by $AMRX Amneal Pharmaceuticals, Inc.

Approved

community read0 votes

indications

investigational

Breast Cancer

all catalysts(7)

approval · 7

News(0)

no news has mentioned this drug yet

brand

EPIRUBICIN HYDROCHLORIDE

generic

EPIRUBICIN HYDROCHLORIDE

indication

Breast Cancer

phase

marketed

EPIRUBICIN HYDROCHLORIDE — FDA approval

EPIRUBICIN HYDROCHLORIDE

EPIRUBICIN HYDROCHLORIDE — FDA approval

EPIRUBICIN HYDROCHLORIDE

EPIRUBICIN HYDROCHLORIDE — FDA approval

EPIRUBICIN HYDROCHLORIDE

EPIRUBICIN HYDROCHLORIDE — FDA approval

EPIRUBICIN HYDROCHLORIDE

EPIRUBICIN HYDROCHLORIDE — FDA approval

EPIRUBICIN HYDROCHLORIDE

EPIRUBICIN HYDROCHLORIDE — FDA approval

EPIRUBICIN HYDROCHLORIDE

EPIRUBICIN HYDROCHLORIDE — FDA approval

EPIRUBICIN HYDROCHLORIDE

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 3

tagApproval14 co-mentions · 7 sources
drugEllence7 co-mentions · 7 sources
companyCipla Ltd7 co-mentions · 7 sources

Trials studying EPIRUBICIN HYDROCHLORIDE

phase2Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)recruitingn=372
phase3A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBCnot yet recruitingn=236
phase2A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)withdrawn